Slingshot members are tracking this event:
Eli Lilly and Company and AstraZeneca Announce Continuation of Pivotal Clinical Trial for People with Early Alzheimer's Disease
Do you think this event is important to the companies below? How will it affect their stock price?
AZD3293 has been shown in Phase 1 studies to reduce levels of amyloid beta in the cerebro-spinal fluid of people with Alzheimer's and healthy volunteers. The progression of Alzheimer's disease is characterized by the accumulation of amyloid plaque in the brain. BACE is an enzyme associated with the development of amyloid beta. Inhibiting BACE is expected to prevent the formation of amyloid plaque and eventually slow the progression of the disease.
Slingshot Insights Explained
Apr 08, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Early Alzheimer's Disease, Azd3293, Amaranth, Oral Beta Secretase Cleaving Enzyme, Daybreak